Published in Biochem Biophys Res Commun on January 02, 2004
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol (2008) 2.22
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem (2009) 1.61
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol (2007) 1.53
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog (2010) 1.38
Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression. J Virol (2006) 1.29
Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One (2010) 1.29
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother (2010) 1.21
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
The genome of tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster. PLoS Genet (2013) 1.13
Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem (2011) 1.13
Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother (2008) 1.11
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10
Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol (2007) 1.10
Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob Agents Chemother (2009) 1.05
Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci (2008) 1.03
Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther (2013) 0.98
Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology (2009) 0.95
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol (2009) 0.94
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother (2012) 0.94
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother (2012) 0.93
Isoform-specific inhibition of cyclophilins. Biochemistry (2009) 0.92
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother (2008) 0.92
Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res (2013) 0.91
Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One (2012) 0.89
Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother (2010) 0.88
Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol (2005) 0.88
Cyclophilins as modulators of viral replication. Viruses (2013) 0.88
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci (2010) 0.88
Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl Infect Dis (2010) 0.88
HSV keratitis: histopathologic predictors of corneal allograft complications. Trans Am Ophthalmol Soc (2008) 0.87
Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J Gen Virol (2010) 0.86
Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J Virol (2012) 0.86
Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol (2011) 0.86
Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob Agents Chemother (2013) 0.86
Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem Pharmacol (2009) 0.86
Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. Drug Target Insights (2007) 0.86
New therapeutic approaches to hepatitis C virus. J Gastroenterol (2009) 0.86
The TPR domain in the host Cyp40-like cyclophilin binds to the viral replication protein and inhibits the assembly of the tombusviral replicase. PLoS Pathog (2012) 0.84
Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses (2010) 0.83
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
Cyclophilin inhibitors as a novel HCV therapy. Viruses (2010) 0.82
Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses (2013) 0.81
BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. J Transplant (2011) 0.81
Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. PLoS One (2014) 0.80
The role of immunophilins in viral infection. Biochim Biophys Acta (2014) 0.80
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Review on immunosuppression in liver transplantation. World J Hepatol (2015) 0.79
Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother (2011) 0.79
Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection. Viruses (2012) 0.79
Recombinant Pseudorabies Virus (PRV) Expressing Firefly Luciferase Effectively Screened for CRISPR/Cas9 Single Guide RNAs and Antiviral Compounds. Viruses (2016) 0.77
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon (2012) 0.76
Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. PLoS One (2016) 0.75
Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice. Sci Rep (2016) 0.75
Chaperones in hepatitis C virus infection. World J Hepatol (2016) 0.75
Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog (2014) 0.75
Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model. World J Gastroenterol (2010) 0.75
A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. PLoS One (2017) 0.75
Integrating multi-omics analyses of Nonomuraea dietziae to reveal the role of soybean oil in [(4'-OH)MeLeu](4)-CsA overproduction. Microb Cell Fact (2017) 0.75
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med (2012) 3.17
MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol (2005) 3.02
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest (2002) 2.74
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology (2002) 2.34
Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med (2002) 2.18
Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol (2012) 2.17
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer (2006) 1.97
CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol (2004) 1.89
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol (2007) 1.75
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Characteristics of international medical graduates who applied to the CaRMS 2002 match. CMAJ (2003) 1.68
Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA (2008) 1.66
Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65
Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis (2008) 1.62
Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. J Biol Chem (2002) 1.61
Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer. JOP (2010) 1.59
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol (2003) 1.57
Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J Infect Dis (2004) 1.55
Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology (2008) 1.53
Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int (2011) 1.49
MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int J Urol (2012) 1.45
Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur Radiol (2012) 1.45
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology (2011) 1.43
Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol (2008) 1.42
Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol (2006) 1.41
A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology (2006) 1.40
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40
Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell (2013) 1.39
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol (2005) 1.39
Enrichment and clonal culture of progenitor cells during mouse postnatal liver development in mice. Gastroenterology (2009) 1.39
Molecular pathology of gastric cancer: research and practice. Pathol Res Pract (2011) 1.39
Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol (2009) 1.39
Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol (2003) 1.37
Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer (2009) 1.34
Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cells (2003) 1.33
Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology (2009) 1.33
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet (2011) 1.31
Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol (2005) 1.30
Senescence marker protein-30 knockout mouse liver is highly susceptible to tumor necrosis factor-alpha- and Fas-mediated apoptosis. Am J Pathol (2002) 1.30
Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology (2002) 1.29
Phylogenetic analysis of spotted fever group rickettsiae based on gltA, 17-kDa, and rOmpA genes amplified by nested PCR from ticks in Japan. Microbiol Immunol (2003) 1.29
Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J Immunol (2003) 1.28
IL-7 Is essential for the development and the persistence of chronic colitis. J Immunol (2007) 1.27
Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2009) 1.27